Independent Research
IOVA Analysis
4 pieces of research on Iovance Biotherapeutics, Inc.. We find the signal management buried in the earnings call.
3signal analyses
1news briefs
latest: Oct 29, 2026
Signal Analysis (2)
Analysis
Iovance Trades Premium Despite 13-Month Cash Runway
Iovance Biotherapeutics trades above the $14.40 analyst consensus price target following September guidance raise, but the company holds only 13 months of cash …
Read analysis →Analysis
Iovance Debuts Sarcoma Data as Cash Runs Low
Iovance presented the first TIL cell therapy data in soft tissue sarcomas at ESMO, expanding the platform beyond melanoma. The company's $300 million cash balan…
Read analysis →